Eiken Chemical : Business Results for the First Nine Months of fiscal year ending March 31, 2023
January 30, 2023 at 10:07 pm
Share
Business Results for the First Nine Months of fiscal year ending March 31, 2023
January 30, 2023
EIKEN CHEMICAL CO., LTD
(Code:4549)
■ Consolidated financial highlights
(Million of yen)
First nine Months of fiscal year ending March 31, 2023 - Consolidated -
Net sales
(Overseas sales)
Operating profit
Ordinary profit
Profit attributable to owners of parent
Results
Ratio
YoY change
33,860
100.0%
2,029
106.4%
6,587
19.5%
△ 73
98.9%
6,999
20.7%
355
105.4%
7,107
21.0%
366
105.4%
5,361
15.8%
325
106.5%
➢ Net sales and operating income increase in revenue and profit. ✓ Demand for COVID-19 detection reagents has increased
✓ Overseas sales decrease because of stock adjustment in some area. ✓ Profit increase by change the product mix.
2
■ Related to COVID-19(SARS-CoV-2) Detection Kit
Trend in orders for the COVID-19 detection kits-
25,000
The 7th
7,000,000
Orders for the detection kits
wave
COVID-19 positives
6,000,000
20,000
The 8th
wave
15,000
4,000,000
3,000,000
Loopamp SARS-CoV-2
10,000
Detection Kit
2,000,000
5,000
1,000,000
0
2020
2021
2022
0
3
4
5
6
7
8
9 10 11 12
1
2
3
4
5
6
7
8
9
10
11
12
1
2
3
4
5
6
7
8
9
10 11
12
Loopamp Realtime Turbidimeter
LoopampEXIA
※ From the website of the Ministry of Health, Labour and Welfare: Covid-19 outbreaks in Japan.
3
■ Sales by Segment -Consolidated-
FIT reagents (OC)
Immunological and serological reagents
Urinalysis test strips
Microbiological reagents
Clinical chemistry reagents
Food and environment category, equipments
Molecular genetics(LAMP)
Medical devices/Others
Total
4
(Million of yen)
First nine
First nine
months
months of
YoY ratio
of FY03/2022
FY03/2023
8,742
8,596
98.3%
7,277
7,440
102.2%
2,900
3,102
106.9%
3,077
3,045
99.0%
479
465
97.1%
1,679
1,646
98.0%
4,680
6,624
141.5%
2,993
2,939
98.2%
31,831
33,860
106.4%
(Million of yen)
33,860
31,831
8,596
8,742
7,440
7,277
3,102
2,900
3,045
3,077
465
479
1,646
1,679
4,680
6,624
2,993
2,939
First nine
First nine
months
months of
of FY03/2022
FY03/2023
■ Sales by Segment - Molecular genetics(LAMP)
➢ Sales of the COVID-19 detection reagents increase because of the 7th wave to 8th wave of the COVID-19 pandemic, driven by the omicron.
➢ License income: 1,462 million yen (previous year: 739 million yen). Temporary Lamp license incomes until the second quarter.
(Million of yen)
First nine monthes
* SARS-CoV-2 is the causative virus of COVID19.
7,445
6,624
6,390
4,391
4,680
Loopamp SARS-CoV-2
Loopamp Realtime Turbidimeter
Detection Kit
LoopampEXIA
Products in a wide range of fields such as medical care,
food and environment using our original technology LAMP.
TB-LAMP (Tuberculosis Test) received WHO
FY03/2021
FY03/2022
FY03/2023
recommendations in 2016 and is currently being sales for
developing countries.
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
EIKEN Chemical Co. Ltd. published this content on 31 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 January 2023 03:06:11 UTC.
EIKEN CHEMICAL CO., LTD. is a Japan-based company principally engaged in the manufacture and sale of test drugs. Through its subsidiaries, the Company involves in the processing, manufacture, purchase and sale of test agents. The products and services include microbial testing reagents, urine testing reagents, immunoserologic testing reagents, biochemical testing reagents and instrument food environment-related media.